Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

Part of paid clinical trials in Duarte, California.

Sponsor
Revolution Medicines, Inc.
Study ID
NCT06128551
Phase
PHASE1/PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Elironrasib — DRUG
    oral tablets
  • Daraxonrasib — DRUG
    oral tablets

Study Details

This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors.

Key Dates

Start date
Nov 14, 2023
Status verified
Apr 2026
Primary completion
Dec 31, 2028
Completion
Jun 30, 2029

Study Design

Enrollment
534 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Elironrasib Monotherapy
    Phase 2 only
  • Experimental: Daraxonrasib Monotherapy
    Phase 2 only
  • Experimental: Daraxonrasib + Elironrasib Combination
    Phase 1b and 2

Primary Outcome Measure

Number of patients with adverse events (AEs) in Phase 1b [ Time Frame: Up to approximately 3 years ]

Central Contacts

Locations (21)

FacilityCityStateZIPSite coordinators
City of HopeDuarteCalifornia91010-
UC IRVINE HealthOrangeCalifornia92868-
UC Davis Comprehensive Cancer CenterSacramentoCalifornia95817-
Stanford Cancer InstituteStanfordCalifornia94305-
University of Colorado Cancer CenterAuroraColorado80045-
Florida Cancer SpecialistsSarasotaFlorida34232-
Moffitt Cancer Center and Research InstituteTampaFlorida33612-
Dana Farber Cancer InstituteBostonMassachusetts02215-
Henry Ford CancerDetroitMichigan48202-
START MidwestGrand RapidsMichigan49546-
Columbia UniversityNew YorkNew York10032-
Memorial Sloan Kettering Cancer CenterNew YorkNew York10065-
NYU Langone HealthNew YorkNew York10032-
University of OklahomaOklahoma CityOklahoma73104-
Sarah Cannon Research InstitueNashvilleTennessee37203-
Mary Crowley Cancer ResearchDallasTexas75230-
MD AndersonHoustonTexas77030-
NEXT DallasIrvingTexas75039-
NEXT Oncology San AntonioSan AntonioTexas78229-
START TexasSan AntonioTexas78229-
NEXT Oncology VirginiaFairfaxVirginia22031-

Find similar trials in Duarte, CA

By condition
Colorectal cancerPancreatic cancer
By specialty
OncologyGI oncology
By research site
City of Hope· Duarte, CAUC IRVINE Health· Orange, CAUC Davis Comprehensive Cancer Center· Sacramento, CAStanford Cancer Institute· Stanford, CAUniversity of Colorado Cancer Center· Aurora, COFlorida Cancer Specialists· Sarasota, FL

Related Studies